Your session is about to expire
← Back to Search
Dulaglutide + Exercise for Type 1 Diabetes (KML002 Trial)
KML002 Trial Summary
This trial will test if a medication and exercise can improve blood flow in people with type 1 diabetes by reducing oxidative stress.
KML002 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKML002 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.KML002 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your C-peptide level is less than 0.6 ng/ml.Your oxygen level is below 90% during screening.I am between 18 and 40 years old.You are allergic to perflutren, which is in the Definity© contrast.I have diabetes with complications like heart disease, stroke, or nerve damage.Your body mass index (BMI) is between 19 and 34.9.I use insulin for my diabetes, either through injections or a pump.I was hospitalized for diabetic ketoacidosis within the last year.I have a condition that stops me from doing exercise tests or training.My non-diabetes medications have not changed in the last 6 months.You have low levels of red blood cells (hemoglobin) if you are a woman or a man, high levels of a type of white blood cells (eosinophils), or a low total white blood cell count.I have not had diabetic ketoacidosis during screening or study admission.You have trouble recognizing when your blood sugar gets too low.I do not have any acute or unstable conditions except for Type 1 Diabetes.I have had type 1 diabetes for more than 5 years.I am taking medication for blood pressure or heart conditions.You have smoked within the last 6 months.Your screening tests show normal results or nothing that would affect your health.Your HbA1c level is less than 8.5%.I have a history of severe stomach or pancreas issues, or thyroid cancer in my family.
- Group 1: Exercise training
- Group 2: Placebo
- Group 3: Dulaglutide
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do I satisfy the criteria to be included in this examination?
"Participants of this medical trial must possess the following characteristics: age between 18 and 40, type 1 diabetes for a minimum of 5 years, HbA1c below 8.5%, body mass index (BMI) in the range 19-27 kg/m2, treatment with insulin only via multiple daily injections or an insulin pump supplemented by sensors, standard test results not clinically significant, C-peptide levels lower than 0.6 ng/ml on average across 6 months preceding screening process , usage of non-diabetic medications that has been stable over past half year and physical activity less than 150 minutes at moderate intensity or 70"
Does this experiment have open enrollment at the moment?
"According to clinicaltrials.gov, the recruitment period for this medical study ended on October 31st 2022 and is no longer actively seeking participants. However, there are currently 1289 other trials that require patient volunteers at this time."
Is Dulaglutide officially sanctioned by the U.S. Federal Drug Administration?
"Dulaglutide has been assessed on a scale of 1 to 3, and our team estimates it to be at level 2. This is because this drug is in Phase 2 trials, giving us some insights into its safety but not yet any information about efficacy."
Is the participant criteria for this trial inclusive of individuals who are older than 35?
"This clinical trial is available to those between 18 and 40 years old. Alternatively, 220 trials are open to minors while 947 studies are limited to elderly patients."
Share this study with friends
Copy Link
Messenger